A systematic review on the relationship between β-blockers and bone health

International Journal of Pharmacology

Volumn 6, Issue 5, 2010, Pages 577-583

  Salari Sharif, P ^a   Abdollahi, M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone metabolism; Fracture risk; Osteoporosis; Review; blocker

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ATENOLOL; ATORVASTATIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARBOXY TERMINAL TELOPEPTIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; CORTICOSTEROID; DEOXYPYRIDINOLINE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROPRANOLOL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; BODY MASS; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FRAGILITY FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHYSICAL ACTIVITY; PROTECTION; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAMPLE SIZE; SEARCH ENGINE; SMOKING; SYSTEMATIC REVIEW;

EID: 77955682498     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.577.583     Document Type: Article

References (41)

1. Abdollahi, M., B. Larijam, R. Rahimi and P. Salari, 2005. Role of oxidative stress in osteoporosis. Therapy, 2: 787-796.
2. Ahima, R.S., 2004. Body fat, leptin and hypothalamic amenorrhea. N. Engl. J. Med., 351: 959-962.
3. Ahima, R.S., C.B. Saper, J.S. Flier and J.K. Elmquist, 2000. Leptin regulation of neuroendocrine systems. Front. Neuroendocrinol., 21: 263-307.
4. Bonnet, N., C. Gadois, E. McCloskey, G. Lemineur, E. Lespessailles, D. Courteix and C.L. Benharnou, 2007. Protective effect of β blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 40: 1209-1216.
5. Cherruau, M., P. Facchinetti, B. Baroukh and J.L. Saffer, 1999. Chemical sympathectomy impairs bone resorption in rats: A role for the sympathetic system on bone metabolism. Bone, 25: 545-551.
6. Cornish, J., K.E. Callon, U. Bava, C. Lin and D. Naotea. 2002. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J. Endocrinol, 175: 405-415.
7. De Vries, F., S. Pouwels, M. Bracke, H.G. Leufkens and C. Cooper et al., 2007a. Use of beta-2 agonists and risk of hip/femur fracture: A population-based case-control study. Pharmacoepidemiol. Drug Safety, 16: 612-619.
8. De Vries, F., P.C. Souverein, P.C. Cooper, H.G.M. Leufkens and T.P. van Staa, 2007b. Use of β-blockers and the risk of hip/femur fracture in the United Kingdom and Netherlands. Calcif Tissue Int., 80: 69-75.
9. Ducy, P., M. Amling, S. Takeda and M. Priemel et al., 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell, 100: 197-207.
10. Eleftenou, F., J.D. Ahn, S. Takeda, M. Starbuck and X. Yang et al, 2005. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature, 434: 514-520.
11. Elefteriou, F., S. Takeda, K. Ebihara, J. Magre and N. Patano et al., 2004. Serum leptin level is a regulator of bone mass. Proc. Natl. Acad. Sci. USA., 101: 3258-3263.
12. Hanley, D.A., J.P. Brown, A. Tenenhouse, W.P. Olszynski and G. Ioannidis et al, 2003. Association among disease conditions, bone mineral density and prevalent vertebral deformities in men and women 50 years of age and older: Cross-sectional results from the Canadian Multicentre Osteoporosis Study. J. Bone Miner. Res., 18: 784-790.
13. Karsenty, G., 2006. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metabolism, 4: 341-348.
14. Lerner, U.H., 2002. Neuropeptidergic regulation of bone resorption and bone formation. J. Musculoskelet. Neuronal Interact, 2: 440-447.
15. Lopez-Sendon, J., K. Swedberg, J. McMurray, J. Tamargo and A.P. Maggioni et al., 2004. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J., 25: 1341-1362.
16. Meisinger, C, M. Heier, O. Lang and A. Doring, 2007. β-blocker use and risk of fractures in men and women from the general population: The MONICA/KORA Augsburg cohort study. Osteoporos. Int., 18: 1189-1195.
17. Minkowitz, B., A.L. Boskey, J.M. Lane, H.S. Pearlman and V.J. Vigorita, 1991. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res., 9: 869-875.
18. Moore, R.E., C.K. Smith, C.S. Bailey, E.F. Voelkel and A.H. Jr. Tashjian, 1993. Characterization of betaadrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner., 23: 301-315.
19. Pasco, J.A., M.J. Henry, G.C. Nicholson, H.G. Schneider and M.A. Kotowicz, 2005. B-blockers reduce bone resorption marker in early postmenopausal women. Ann. Human Biol., 32: 738-745.
20. Pasco, J.A., M.J. Henry, K.M. Sanders, M.A. Kotowicz, E. Seeman and G.C. Nicholson, 2004. B-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res., 19: 19-24.
21. Perez-Castrillon, J.L., G. Vega, L. Abad, A. Sanz, M. Mendo, M.G. Ponero and A. Duenas, 2007. Effect of β-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine., 74: 259-262.
22. Reid, I.R., G.D. Gamble, A.B. Grey, D.M. Black, K.E. Ensrud, W.S. Browner and D.C. Bauer, 2005a. β-blocker use, BMD and fractures in the study of osteoporotic fractures. J. Bone. Miner. Res., 20: 613-618.
23. Reid, I.R., J. Lucas, D. Wattie, A. Home, M. Bolland, G.D. Gamble, J.S. Davidson and A.B. Grey 2005b. Effects of a β-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metabial, 90: 5212-5216.
24. Rejnmark, L., P. Vestergaard, M. Kassem, B.R. Chnstoffersen, N. Kolthoff, K. Brixen and L. Mosekilde, 2004. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int., 75: 365-372.
25. Rejnmark, L., P. Vestergaard and L. Mosekilde, 2006. Treatment with beta-blockers, ACE inhibitors and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens., 24: 581-589.
26. Salari, P., B. Larijaniand, M. Abdollahi, 2008a. Association of hyperhomocysteinemia with osteoporosis: A systematic review. Therapy, 5: 215-222.
27. Salari, P., A. Rezaie, B. Larijani and M. Abdollahi, 2008b. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med. Sci. Monitor, 14: RA37-44.
28. Salari, P. andM. Abdollahi, 2009. Controversial effects of non-steroidal anti-inflammatory drugs on bone: a review. Inflamm. Allergy Drug Targets, 8: 169-175.
29. Salari Sharif, P. and M. Abdollahi, 2010. The role of platelets in bone remodeling. Inflamm. Allergy Drug Tragets, 2010 Jun 3. [Epub Ahead of Print].
30. Salari-Sharif, P., M. Asalforoush, F. Ameri, B. Larijani and M. Abdollahi, 2010. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age, 32: 179-186.
31. Schlienger, R.G., M.E. Kraenzlin, S.S. Jickand, C.R. Meier, 2004. Use of β-blockers and risk of fractures. JAMA, 292: 1326-1332.
32. Sosa, M., P. Saavedra, J. Mosquera, R. Perez-Cano and J. Olmos et at, 2010. Beta-blocker use is associated with fragility in postmenopausal women with coronary heart disease. Aging Clin. Exp. Res.,
33. Takeda, K.L., F. Elefteriou, R. Levasseur, X. Liu and L. Zhaox, 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell, 111: 305-317.
34. Takeuchi, T., T. Tsuboi, M. Arai and A. Togari, 2000. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol, 61: 579-586.
35. Togari, A., M. Arai, S. Mizutani, Y. Koshihara and T. Nagatsu, 1997. Expression of inRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblastic and human osteogenic sarcoma cells. Neurosci. Lett, 233: 125-128.
36. Togari, A., 2002. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervations of osteoblastic and osteoclastic cells. Microsc. Res. Tech., 58: 77-84.
37. Togari, A. and M. Arai, 2008. Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption. J. Pharmacol. Sci., 106: 542-546.
38. Toh, S. and S. Hernandez-Diaz, 2007. Statins and fracture risk. A systematic review. Pharmacoepidemiol. Drug Safety, 16: 627-640.
39. Turker, S., V. Karatosun and Gunal, 2006. Beta-blockers increase bone mineral density. Clin. Orthop. Relat. Res., 443: 73-74.
40. Wiens, M., M. Etminan, S.S. Gill and B. Takkouche, 2006. Effects of antihypertensive drug treatment on fracture outcomes: a meta-analysis of observational studies. J. Int. Med., 260: 350-362.
41. Yousefzadeh, G., B. Larijani, B. Mohammadirad, R. Heshmat, G. Dehghan, R. Rahimi and M. Abdollahi, 2006. Determination of oxidative stress status and concentration of TGF-βl in the blood and saliva of osteoporotic subjects. Ann. N. Y. Acad. Sci., 1091: 142-150.